Li H, Liu J, Ouyang Q, Wang S, et al. Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial. Lancet Oncol 2025;26:1563-1574.
PMID: 41308673